France alerts 1.6M women to meningioma risk from desogestrel contraceptives

France's drug agency is notifying 1.6 million women who used desogestrel-based contraceptives of a low but increased risk of meningioma, a brain tumor. The agency advises monitoring for neurological symptoms but does not recommend stopping treatment. This is a regulatory health alert with potential implications for contraceptive prescribing and patient anxiety, though the absolute risk remains low.